Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02477670 · ClinicalTrials.gov registry record · Phase 2

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia

A Phase 2 study of Schizophrenia, sponsored by Avanir Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
145
Enrollment target
17
Study locations

NCT02477670 is a Phase 2 study of Schizophrenia that has completed, run by Avanir Pharmaceuticals. The registered enrollment target is 145 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (34% lower). The trial reports 17 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02477670, a Phase 2 study of Schizophrenia, has completed, sponsored by Avanir Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
145 participants
Enrollment target
17
Study locations

Study Summary

The objectives of this 12-week study are to evaluate the efficacy, safety, and tolerability of AVP-786 as an adjunctive treatment compared with placebo in patients with residual schizophrenia.

Conditions Studied

Schizophrenia

Interventions

  • DRUG Placebo
  • DRUG AVP-786

Study Locations (17)

California

  • - Cerritos
  • - Garden Grove
  • - National City
  • - Oakland
  • - San Diego

New York

  • - Jamaica
  • - New York
  • - Rochester

Georgia

  • - Atlanta
  • - Augusta

Massachusetts

  • - Boston
  • - Worcester

District of Columbia

  • - Washington D.C.

Florida

  • - Orlando

Illinois

  • - Chicago

Michigan

  • - Grand Rapids

Trial Details

FieldValue
Enrollment Target 145 participants
Start Date 2015-09
Est. Completion 2017-07-21
Phase Phase 2

Sponsor

Avanir Pharmaceuticals

15 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02477670

The ClinicalTrials.gov registry entry for NCT02477670 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (34% lower). The listed sponsor is Avanir Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02477670 reports 17 study locations spanning 9 distinct geographic areas - top geographies include California, New York, Georgia.

Frequently Asked Questions

What is clinical trial NCT02477670 about?

NCT02477670 is a clinical study titled "Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia". The objectives of this 12-week study are to evaluate the efficacy, safety, and tolerability of AVP-786 as an adjunctive treatment compared with placebo in patients with residual schizophrenia.

What is the current status of trial NCT02477670?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 145 participants. The study started on 2015-09. Estimated completion is 2017-07-21.

What conditions does trial NCT02477670 study?

This clinical trial studies the following conditions: Schizophrenia.

What interventions are being tested in trial NCT02477670?

The interventions under investigation include: Placebo (DRUG), AVP-786 (DRUG).

Who is sponsoring clinical trial NCT02477670?

This trial is sponsored by Avanir Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02477670 being conducted?

This trial has 17 study locations across California, District of Columbia, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Schizophrenia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.